Treatment News : Viral Load Is Best Predictor of CD4 Loss Among South Africans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 4, 2014

Viral Load Is Best Predictor of CD4 Loss Among South Africans

Higher HIV viral loads are linked to a faster depletion of CD4 cells among South Africans not taking antiretrovirals (ARVs), aidsmap reports. Publishing their findings in PLOS ONE, researchers studied 1,106 people with subtype C of HIV whose CD4s were above 200 and who were treatment naive at the outset and who had positive tuberculosis skin tests. (The participants had been recruited to a study testing a preventive TB treatment.)

With recruitment starting in 2003, the investigators followed the participants for a median 44 months, regularly monitoring their CD4s and viral loads. The participants had a median CD4 count of 490 and a median viral load of 16,050 upon starting the study.

The average CD4 drop was 38.4 cells per year, which is a less steep decline than is typically found among those with subtype B of HIV, the most common in the United States. Those whose viral loads were above 10,000 had an average annual decline of 11 percent, compared with 14 percent for those with viral loads above 100,000.

Twenty-two percent of the participants had a baseline viral load above 100,000, which put them at high risk of transmitting the virus; yet they were still ineligible to receive ARVs under current South African guidelines. The study suggested that a significant proportion of people in South Africa may thus spend a good deal of time living with highly infectious virus before receiving the benefits of treatment as prevention (TasP), considering that ARVs greatly reduce their likelihood of passing on the virus.

To read the aidsmap story, click here.

To read the study, click here.

Search: Viral load, CD4, South Africa, aidsmap, PLOS ONE, HIV.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    Newhopenate
    New Hope
    Pennsylvania


    Sexynyrican
    Brooklyn
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.